CytomX Therapeutics, Inc.
CTMX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $526 | $293 | $55 | $83 |
| - Cash | $34 | $49 | $48 | $38 |
| + Debt | $6 | $7 | $8 | $9 |
| Enterprise Value | $498 | $251 | $16 | $54 |
| Revenue | $6 | $19 | $51 | $38 |
| % Growth | -68% | -63.4% | 33.7% | – |
| Gross Profit | $6 | $19 | $51 | $38 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$14 | -$1 | $23 | $18 |
| % Margin | -235.4% | -5% | 45.2% | 47.5% |
| Net Income | -$14 | -$0 | $24 | $19 |
| % Margin | -238.6% | -0.8% | 46.2% | 49.6% |
| EPS Diluted | -0.09 | -0.001 | 0.27 | 0.24 |
| % Growth | -7,400% | -100.4% | 12.5% | – |
| Operating Cash Flow | -$16 | -$16 | -$21 | -$20 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$15 | -$16 | -$21 | -$20 |